FDA advisers recommend approval of Alzheimer's drug Lecanemab.
TL;DR Summary
An advisory panel for the US FDA voted unanimously that the Alzheimer’s drug lecanemab shows “clinical benefit” for the treatment of the disease, paving the way for the medication to be considered for full FDA approval. Lecanemab is one of the first dementia drugs that appears to slow the progression of cognitive decline. The drug is not a cure but works by binding to amyloid beta, a hallmark of Alzheimer’s disease. A decision from the FDA is expected by July 6.
- FDA advisers vote that lecanemab shows benefit as an Alzheimer’s treatment CNN
- FDA advisors endorse Alzheimer’s treatment Leqembi paving way for full approval this summer CNBC
- Biogen Stock Halted as FDA Committee Considers Alzheimer's Drug The Wall Street Journal
- Alzheimer's Drug Clears Major Hurdle Toward Full Approval Medpage Today
- Pharmalittle: FDA panel to review Alzheimer's treatment; FDA advisers back approval of RSV drug for children STAT
Reading Insights
Total Reads
0
Unique Readers
1
Time Saved
5 min
vs 6 min read
Condensed
93%
1,138 → 81 words
Want the full story? Read the original article
Read on CNN